Serina Therapeutics Inc., a clinical-stage biotechnology company, has released its financial results for the second quarter ending June 30, 2025. The company reported a net loss of $6.4 million for the quarter, a significant turnaround from the net income of $5.2 million in the same period in 2024. Revenue for the quarter increased to $130,000, up from $51,000 in the corresponding period last year, with revenues entirely derived from grants provided by the National Institutes of Health. Operating expenses rose to $5.7 million from $3.9 million in the previous year, contributing to the overall net loss. Cash and cash equivalents stood at $6.0 million as of June 30, 2025, with projections indicating that these funds will support operations into the fourth quarter of 2025. In terms of business developments, Serina secured $5 million in funding from strategic shareholders in April 2025 to advance the development of SER-252, its lead candidate for treating advanced Parkinson's disease. Additionally, the company initiated an at-the-market offering program with the potential to raise $13.3 million through share sales, having already issued shares worth $1.2 million by early August 2025. The company is preparing to commence a Phase 1 clinical trial for SER-252 in the fourth quarter of 2025.